title: Anticoagulation in the antiphospholipid syndrome.
abstract: Our objectives were to evaluate thrombotic complications in patients with lupus anticoagulant fulfilling Sapporo criteria, anticoagulated with an intended INR 2.0-3.0 due to venous and arterial thrombosis. In our series standard anticoagulation was safe and efficacious in preventing recurrences in patients with systemic lupus erythematosus, with other thrombophilia and with arterial thrombosis.
authors.forename: Patricia
authors.initials: P
authors.lastname: Casais
authors.forename: María F
authors.initials: MF
authors.lastname: Alberto
authors.forename: Laura C
authors.initials: LC
authors.lastname: Gennari
authors.forename: Silvia H
authors.initials: SH
authors.lastname: Grosso
authors.forename: Susana S
authors.initials: SS
authors.lastname: Meschengieser
authors.forename: María A
authors.initials: MA
authors.lastname: Lazzari
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D019934:International Normalized Ratio; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control
chemical_list: D000925:Anticoagulants